More Articles

European trade organizations worried about pharmacovigilance fees Policies & Legislation | Posted 07/03/2014

Some of Europe’s major trade associations have expressed their concerns over fees being proposed by the European Medicines Agency (EMA) as part of new European Union (EU) pharmacovigilance rules.

Biosimilars approved in Japan Biosimilars/General | Posted 07/03/2014

Last update: 22 April 2016In Japan, the regulatory body for the approval of medicines, including biologicals, is the Ministry for Health Labour and Welfare (MHLW).

Actavis to acquire specialty drugmaker Forest Labs Pharma News | Posted 07/03/2014

US-based generic drugmaker Actavis is set to grow even bigger, with the acquisition of US-based Forest Laboratories (Forest Labs), according to an announcement by the companies on 18 February 2014.

Kissei makes biosimilars deal with Alteogen Biosimilars/News | Posted 07/03/2014

Japan-based Kissei Pharmaceutical (Kissei) announced on 13 February 2014 that the company had entered into a collaboration agreement with South Korean biologicals company Alteogen.

Teva and Ranbaxy settle unlawful competition investigation Generics/News | Posted 07/03/2014

New York Attorney General Eric Schneiderman announced on 19 February 2014 that he had reached a settlement with generics makers Ranbaxy Pharmaceuticals (Ranbaxy) and Teva Pharmaceuticals (Teva) for...

Nigerian guidelines for biosimilars Guidelines | Posted 07/03/2014

Last update:  11 March 2014The regulatory body for approval of medicines in Nigeria is the National Agency for Food and Drugs Administration and Control (NAFDAC). The agency, through its Regul...

EU majority says same INNs for biosimilars Biosimilars/General | Posted 28/02/2014

According to recently published summary minutes from an October 2013 meeting of the European Commission’s Pharmaceutical Committee, the majority of EU Member States agree that biosimilars should ha...

Inflammatory arthritis: auditioning for the role of biosimilar Biosimilars/Research | Posted 28/02/2014

Targeted biological therapies have proven themselves highly effective in the treatment of inflammatory joint diseases, but their benefits are restricted by cost. Biosimilars of these therapies woul...